TNFSF13

TNFSF13, also known as tumor necrosis factor ligand superfamily member 13 or APRIL (A Proliferation-Inducing Ligand), is a member of the tumor necrosis factor (TNF) superfamily of proteins. It plays a critical role in immune regulation, particularly in B cell activation, differentiation, and survival. APRIL is expressed by various cell types, including dendritic cells, monocytes, fibroblasts, and epithelial cells, and it exerts its effects by binding to specific receptors on target cells.

The primary receptors for APRIL are TNFRSF13B (BCMA, B-cell maturation antigen) and TNFRSF13C (TACI, transmembrane activator and calcium-modulator and cyclophilin ligand interactor). These receptors are predominantly expressed on B cells, plasma cells, and some T cells. APRIL signaling promotes B cell proliferation, antibody production, and plasma cell differentiation, contributing to humoral immunity. It also plays a role in the survival of these cells, particularly under stress conditions.

APRIL is involved in autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, where dysregulated B cell activity is implicated. Additionally, it has been linked to certain cancers, including multiple myeloma, where elevated APRIL levels may support tumor growth and resistance to therapy. Research into APRIL’s mechanisms has identified potential therapeutic targets for autoimmune disorders and malignancies.

Structurally, APRIL is a type II transmembrane protein that is cleaved and secreted as a soluble cytokine. Its expression is regulated by inflammatory signals, cytokines, and other immune modulators. The balance of APRIL signaling is crucial for maintaining immune homeostasis, and its dysregulation can lead to pathological conditions. Further studies continue to elucidate its precise roles in health and disease.